| 08/12 | SYNLAB : Deutsche Bank reiterates its Buy rating | MD |
| 08/11 | SYNLAB AG Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
| 08/11 | SYNLAB : JP Morgan sticks Neutral | MD |
| 08/11 | TRANSCRIPT : SYNLAB AG, Q2 2022 Earnings Call, Aug 11, 2022 | CI |
| 08/11 | SYNLAB AG Revises Earnings Guidance for the Fiscal Year 2022 | CI |
| 08/03 | UnitedHealth struggling to sell Brazilian unit Amil - sources | RE |
| 08/03 | EXCLUSIVE : UnitedHealth struggling to sell Brazilian unit Amil | RE |
| 08/03 | UnitedHealth struggling to sell Brazilian unit Amil | RE |
| 08/01 | UBS Adjusts Dr. Lal Pathlabs' Price Target to 2,700 Indian Rupees From 2,800 Rupees, Ke.. | MT |
| 07/29 | Dr. Lal PathLabs' Consolidated Net Profit Slides in Fiscal Q1; Shares Jump 6% | MT |
| 07/28 | TRANSCRIPT : Dr. Lal PathLabs Limited, Q1 2023 Earnings Call, Jul 28, 2022 | CI |
| 07/28 | Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, P.. | CI |
| 07/28 | Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, .. | CI |
| 07/26 | UBS Adjusts Dr. Lal Pathlabs' Price Target to 2,800 Indian Rupees From 3,700 Rupees, Ke.. | MT |
| 07/19 | SYNLAB : Buy rating from Barclays | MD |
| 07/15 | SYNLAB : Deutsche Bank gives a Buy rating | MD |
| 07/11 | SYNLAB : Jefferies reiterates its Buy rating | MD |
| 06/30 | Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31,.. | CI |
| 06/21 | SYNLAB : Gets a Neutral rating from JP Morgan | MD |
| 06/21 | SYNLAB Seeks M&A | CI |
| 06/21 | TRANSCRIPT : SYNLAB AG - Analyst/Investor Day | CI |
| 06/09 | Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31,.. | CI |
| 06/08 | SYNLAB : Receives a Buy rating from Deutsche Bank | MD |
| 05/31 | SYNLAB : Barclays maintains a Buy rating | MD |
| 05/25 | SYNLAB : JP Morgan remains Neutral | MD |
| 05/20 | Nomura Adjusts Dr. Lal Pathlabs' Price Target to 1,771 Indian Rupees From 2,465 Rupees,.. | MT |
| 05/17 | TRANSCRIPT : Dr. Lal PathLabs Limited, Q4 2022 Earnings Call, May 17, 2022 | CI |
| 05/17 | Dr. Lal Pathlabs Limited Proposes Final Dividend for the Year Ended March 31, 2022 | CI |
| 05/17 | Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year .. | CI |
| 05/13 | TRANSCRIPT : Diagnósticos da América S.A., Q1 2022 Earnings Call, May 13, 2022 | CI |
| 05/13 | SYNLAB : Receives a Buy rating from Deutsche Bank | MD |
| 05/13 | SYNLAB : JP Morgan sticks Neutral | MD |
| 05/12 | SYNLAB : Barclays reiterates its Buy rating | MD |
| 05/12 | TRANSCRIPT : SYNLAB AG, Q1 2022 Earnings Call, May 12, 2022 | CI |
| 05/12 | SYNLAB : Gets a Neutral rating from JP Morgan | MD |
| 05/12 | SYNLAB : Jefferies reaffirms its Buy rating | MD |
| 05/12 | SYNLAB AG Revises Earnings Guidance for 2022 | CI |
| 05/12 | Diagnósticos da América S.A. Reports Earnings Results for the First Quarter Ended March.. | CI |
| 05/12 | SYNLAB AG Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/02 | DIAGNÓSTICOS DA AMÉRICA S.A.(BOVESPA : DASA3) added to Brazil Mid-Large Cap Index | CI |
| 05/01 | Certain Ordinary Bearer Shares of SYNLAB AG are subject to a Lock-Up Agreement Ending o.. | CI |
| 04/29 | UBS Adjusts Guangzhou Kingmed Diagnostics' Price Target to 97 Yuan From 100 Yuan, Keeps.. | MT |
| 04/26 | Guangzhou Kingmed Diagnostics Group Co., Ltd. Reports Earnings Results for the First Qu.. | CI |
| 04/26 | Certain Ordinary Bearer Shares of SYNLAB AG are subject to a Lock-Up Agreement Ending o.. | CI |
| 04/20 | UBS Adjusts Guangzhou Kingmed Diagnostics' Price Target to 100 Yuan From 230 Yuan, Keep.. | MT |
| 04/11 | Fitch Confirms Synlab's BB Rating Citing Large, Stable European Operations | MT |
| 04/11 | SYNLAB : Deutsche Bank reiterates its Buy rating | MD |
| 04/07 | Moody's Upgrades Synlab Outlook To Positive, Affirms Long-Term Rating | MT |
| 03/28 | Diagnósticos da América S.A. Reports Earnings Results for the Full Year Ended December .. | CI |
| 03/24 | SYNLAB AG (DB : SYAB) announces an Equity Buyback for 660,566 shares, for €16.51 mill.. | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
